COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Applications Site Reactions After Injection of Insulin Detemir and Saline in Subjects With Diabetes (APPLY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00607737
Recruitment Status : Completed
First Posted : February 6, 2008
Last Update Posted : September 3, 2012
Novo Nordisk A/S
Information provided by (Responsible Party):
Lise Tarnow, Steno Diabetes Center Copenhagen

Brief Summary:

To compare application site reactions after superficial and deep subcutaneous and intradermal injections of insulin detemir and saline in patients with diabetes

- The patient serves as his own control, n=100 patients with diabetes

Condition or disease Intervention/treatment Phase
Diabetes Mellitus Drug: insulin detemir Drug: saline Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: Doubleblind, Randomised, Single Centre Investigator Sponsored Study of Applications Site Reactions After Deep and Superficial Subcutaneous and Intradermal Injection of Insulin Detemir and Saline in Subjects With Diabetes Mellitus
Study Start Date : January 2008
Actual Primary Completion Date : June 2009
Actual Study Completion Date : July 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
insulin detemir
Drug: insulin detemir
3 cutaneous injections

Placebo Comparator: 2
Drug: saline
3 cutaneous injections

Primary Outcome Measures :
  1. laser doppler blood flow [ Time Frame: 10 minutes - 7 days ]

Secondary Outcome Measures :
  1. clinical signs [ Time Frame: 10 min - 7 days ]
  2. insulin detemir specific antibodies [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diabetes mellitus
  • HbA1c<11 %
  • BMI: 20-35 kg/m2
  • Insulin detemir naive
  • Basal insulin dose>20E

Exclusion Criteria:

  • Known allergy to study drug
  • Current steroid or antiallergic treatment
  • Lipodystrophy
  • Change in insulin and antihypertensive treatment < 30 days
  • Smokers or alcoholics

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00607737

Layout table for location information
Steno Diabetes Center
Gentofte, Denmark, 2820
Sponsors and Collaborators
Lise Tarnow
Novo Nordisk A/S
Layout table for investigator information
Principal Investigator: LIse Tarnow, md Steno Diabetes Center Copenhagen
Additional Information:
Layout table for additonal information
Responsible Party: Lise Tarnow, professor, Steno Diabetes Center Copenhagen Identifier: NCT00607737    
Other Study ID Numbers: APPLY
EudraCT 2007-005677-59
First Posted: February 6, 2008    Key Record Dates
Last Update Posted: September 3, 2012
Last Verified: August 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin Detemir
Hypoglycemic Agents
Physiological Effects of Drugs